Avanir Pharmaceuticals announces Zenvia safety and efficacy data
AVANIR Pharmaceuticals announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia in the treatment of patients with pseudobulbar affect. :theflyonthewall.com
News For AVNR From The Last 14 Days
Check below for free stories on AVNR the last two weeks.
There are 4 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.